[ET Net News Agency, 26 October 2021] WUXI BIO (02269) rose 3.23% to HK$121.5.
It hits an intra-day high of HK$121.5, and an intra-day low of HK$118.1. The total
shares traded was 5.42 million, with a value of HK$648.7m. The active buy/sell ratio is
59:41, with net buying turnover of HK$107.16m. MERRILL LYNCH FE accounts for greatest net
responsive buying turnover of HK$62.44m, with volume weighted average price of HK$119.505.
FUTU SEC INT'L accounts for greatest net responsive selling turnover of HK$44.61m, with
volume weighted average price of HK$120.052. The stock has risen a combined 7.43% over the
past 3 consecutive trading days.
The Hang Seng Index now fell 83 points, or 0.32% to 26,048; the Hang Seng China
Enterprises Index now fell 69 points, or 0.75% to 9,252; the Hang Seng TECH Index now fell
90 points, or 1.35% to 6,653; with an overall turnover of HK$56.22b.
The SSE Composite Index now rose 1 points, or 0.05% to 3,611, with an overall turnover
of RMB303.97b.
The SZSE Component Index now rose 36 points, or 0.25% to 14,632, with an overall
turnover of RMB196.97b.
Basic Information
=================
-----------------------------------
Nominal 121.500 % Chg +3.23%
High 121.500 Low 118.100
Shares Tr 5.42m Turnover 648.7m
10-D SMA 114.500 %H.V 54.440
20-D SMA 117.130 VWAP 119.724
50-D SMA 117.610 RSI14 55.600
-----------------------------------
Status: Active buy/sell ratio is 59:41, with net buying turnover of HK$107.16m, rising a
combined 7.43% over the past 3 consecutive trading days
Performance of stocks in the same sector or of relevance
========================================================
Stock (Code) Price (HK$) Change (%)
-----------------------------------------------
WUXI BIO (02269) 121.50 +3.23
GENSCRIPT BIO (01548) 33.80 Unchanged
INNOVENT BIO (01801) 75.70 -0.39
JXR (01951) 12.72 -1.40
TIGERMED (03347) 150.00 -1.57
BEIGENE (06160) 227.40 -0.18
CANSINOBIO-B (06185) 215.20 -2.98
ASCENTAGE-B (06855) 30.05 -5.06
AKESO-B (09926) 46.80 -1.78
KINTOR PHARMA-B (09939) 41.25 -5.17
-----------------------------------------------
(ed)